公开(公告)号：WO2018129206A1

公开(公告)日：2018-07-12

申请号：PCT/US2018/012412

申请日：2018-01-04

Applicant: SHIMOJANI, LLC

Inventor： KAUVAR, Lawrence M. ,  JANIGRO, Damir

IPC: A61K31/275 ,  A61K31/277 ,  A61K31/404

Abstract: Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.

公开(公告)号：WO2017127834A1

公开(公告)日：2017-07-27

申请号：PCT/US2017/014621

申请日：2017-01-23

Applicant: SAND, Bruce, J.

Inventor： SAND, Bruce, J.

IPC: A61F13/00 ,  A61K31/164 ,  A61K31/351

CPC classification number: A61K9/0014 ,  A61F13/00063

Abstract: Improved formulations that combine chemical permeation enhancers with additional agents so that the formulations simultaneously penetrate both lipid and cellular matrices provide effective transdermal delivery of active agents.

Abstract translation: 将化学渗透增强剂与另外的试剂组合的改进的制剂使得制剂同时渗透脂质和细胞基质提供活性剂的有效透皮递送。

公开(公告)号：WO2017083592A1

公开(公告)日：2017-05-18

申请号：PCT/US2016/061444

申请日：2016-11-10

Applicant: CELATOR PHARMACEUTICALS, INC. ,  OREGON HEALTH & SCIENCES UNIVERSITY

Inventor： GORDON, Max ,  TARDI, Paul ,  TYNER, Jeffrey ,  MAYER, Lawrence

IPC: A61K31/00 ,  A61P35/00 ,  A61P35/02 ,  C12Q1/68

CPC classification number: A61K31/7068 ,  A61K31/44 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/704 ,  C12Q1/68 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  A61K2300/00

Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

Abstract translation: 用于鉴定适于用CPX-351治疗的携带癌症的受试者的诊断方法包括来自候选受试者的细胞的遗传和离体测试。 与CPX-351和FLT-3抑制剂联合治疗可改善CPX-351摄取和毒性。

公开(公告)号：WO2017082978A1

公开(公告)日：2017-05-18

申请号：PCT/US2016/045877

申请日：2016-08-05

Applicant: SOLUDOT LLC

Inventor： NILES, Walter, D. ,  GREY, Jonathan ,  GREY, Katherine, R. ,  HITTLE, Thomas, K.

IPC: G01N33/50 ,  B05B1/00

CPC classification number: B01L3/0268 ,  B01L2200/143 ,  B01L2400/0415 ,  B01L2400/0475 ,  B41J2/07 ,  B41J2/085 ,  B41J2/09 ,  B41J2/175 ,  B41J2/17596 ,  B41J2/18 ,  C12M29/06 ,  C12M41/48 ,  G01N35/1009 ,  G01N35/1011 ,  G01N35/1016 ,  G01N2035/1041

Abstract: A method to obtain high-throughput printing or dispensing of biological samples, especially for use in assay methods employs a continuous flow inkjet printer modified to dispense suitable- sized droplets of biocompatible solutions containing said biological samples.

Abstract translation: 获得生物样品的高通量印刷或分配的方法，特别是用于测定方法的方法采用连续流喷墨打印机，其被修改以分配包含所述生物样品的合适大小的生物相容性溶液液滴。 / p>

公开(公告)号：WO2015134928A2

公开(公告)日：2015-09-11

申请号：PCT/US2015/019285

申请日：2015-03-06

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY

Inventor： MORITZ, Robert, L. ,  SARTAIN, Mark ,  SPACIL, Zdenek ,  KUSEBAUCH, Ulrike ,  CAMPBELL, David

IPC: G01N33/569 ,  C07K7/08

CPC classification number: G01N33/5695 ,  G01N33/00

Abstract: Point of care methods to detect the probability or status of tuberculosis infection in individuals by determining presence or absence of one or more peptide of SEQ ID NOS: l-22 in a biological fluid of a subject are described. These methods may be assays based on affinity reagents specifically reactive with these peptides.

Abstract translation: 描述了通过测定受试者的生物流体中存在或不存在SEQ ID NO：1-22的一种或多种肽来检测个体中结核病感染的概率或状态的观察点方法。 这些方法可以是基于与这些肽特异性反应的亲和试剂的测定法。

公开(公告)号：WO2013059133A1

公开(公告)日：2013-04-25

申请号：PCT/US2012/060293

申请日：2012-10-15

Applicant: CELATOR PHARMACEUTICALS INC.

Inventor： CABRAL-LILLY, Donna ,  MAYER, Lawrence ,  TARDI, Paul ,  WATKINS, David ,  ZENG, Yi

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/19 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  A61K47/26

Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.

Abstract translation: 公开了具有两种或多种包封的药物的冻干脂质体制剂。 这些制剂显示优异的药物保留特征，并且还保持冻干和重构后的尺寸分布。

公开(公告)号：WO2012155098A1

公开(公告)日：2012-11-15

申请号：PCT/US2012/037629

申请日：2012-05-11

Applicant: NOVARX CORPORATION ,  FAKHRAI, Habib ,  SHAWLER, Daniel, L.

Inventor： FAKHRAI, Habib ,  SHAWLER, Daniel, L.

IPC: G01N33/53

CPC classification number: G01N33/57488 ,  G01N33/6854 ,  G01N2800/52

Abstract: The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or nonresponse of pretested populations of subjects.

Abstract translation: 本发明涉及一种通过检测血浆或血清中抗体水平升高来预测可能对免疫治疗有反应的个体的方法，其中所述抗体是预先测试的受试者群体的反应或不响应的特征。

公开(公告)号：WO2012112714A1

公开(公告)日：2012-08-23

申请号：PCT/US2012/025299

申请日：2012-02-15

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY ,  WANG, Kai ,  ZHANG, Shile ,  GALAS, David

Inventor： WANG, Kai ,  ZHANG, Shile ,  GALAS, David

IPC: C12Q1/68

CPC classification number: C12Q1/6851 ,  C12Q1/6883 ,  C12Q2600/178 ,  C40B20/00 ,  C12Q2525/173 ,  C12Q2525/191 ,  C12Q2525/207

Abstract: Improved methods to quantitate RNA in biological or other analytical samples employ extended RNAs containing adaptors at the 5' end and polyA sequences coupled to a tag at the 3 end. The invention method is particularly useful in quantitating microRNAs as primers can be used that need not complement the non-conserved 3' ends of these molecules.

Abstract translation: 在生物或其他分析样品中定量RNA的改进方法使用在5'末端含有衔接子的延伸RNA，并在3端与polyA序列偶联。 本发明方法特别可用于定量微小RNA，因为可以使用不需要补充这些分子的非保守3'末端的引物。

公开(公告)号：WO2011097528A1

公开(公告)日：2011-08-11

申请号：PCT/US2011/023814

申请日：2011-02-04

Applicant: INSTITUTE FOR SYSTEMS BIOLOGY ,  GALAS, David ,  DUDLEY, Aimee ,  WANG, Kai

Inventor： GALAS, David ,  DUDLEY, Aimee ,  WANG, Kai

IPC: C12Q1/68

CPC classification number: C12Q1/6804 ,  C12Q1/6813 ,  C12Q2539/101 ,  C12Q2537/113 ,  C12Q2525/161 ,  C12Q2525/155

Abstract: Disclosed are compositions and methods for detecting target RNA molecules. A specialized DNA probe can be used to form RNA/DNA hybrids with target RNA molecules. Separation of the RNA/DNA hybrids increases the ease and sensitivity of detection and quantitation of the target RNA molecules.

Abstract translation: 公开了用于检测靶RNA分子的组合物和方法。 可以使用专门的DNA探针来形成具有靶RNA分子的RNA / DNA杂交体。 RNA / DNA杂交体的分离增加了目标RNA分子的检测和定量的易感性和灵敏度。

公开(公告)号：WO2011088244A1

公开(公告)日：2011-07-21

申请号：PCT/US2011/021187

申请日：2011-01-13

Applicant: APT THERAPEUTICS, INC. ,  CHEN, Ridong ,  JEONG, Soon, Seog

Inventor： CHEN, Ridong ,  JEONG, Soon, Seog

IPC: C07K14/435

CPC classification number: C12N9/14 ,  C07K14/70596

Abstract: This invention provides a new class of enhanced apyrases (EN-apyrases) with superior pharmacokinetic, pharmacodynamic, and pharmacochemical properties and which can be purified using simplified procedures. The invention further provides constructs for transforming a cell to produce these EN-apyrases. The EN-apyrase construct comprises sequences encoding a signal sequence, a linker, and a soluble apyrase. Also provided are preparations of apyrases and methods for producing apyrase in culture cells and purification thereof.

Abstract translation: 本发明提供了具有优异的药代动力学，药效学和药理学性质的新一类增强的apyrases（EN-apyrases），并且可以使用简化的程序纯化。 本发明还提供了用于转化细胞以产生这些EN-脱酰酶的构建体。 EN-脱酰酶构建体包含编码信号序列，接头和可溶性apyrase的序列。 还提供了apyrases的制剂和在培养细胞中产生apyrase的方法及其纯化。